μ-opioid

The μ-opioid receptor (MOR, also written mu-opioid receptor) is a protein embedded in nerve cell membranes that serves as the principal target through which opioid drugs produce their effects. Of the three classical opioid receptor subtypes — μ, κ, and δ — the μ subtype is most directly responsible for pain relief, euphoria, and the life-threatening respiratory depression that defines opioid overdose.

The body produces its own molecules that bind here: endorphins and enkephalins are the best-known endogenous opioids, released during exercise, stress, and certain emotional states. Opioid drugs work because they mimic or enhance these natural signals, but with greater potency and duration than the body's own chemistry.

How it works · its role

The μ-opioid receptor belongs to the G protein-coupled receptor family. When an opioid molecule binds to it, the receptor activates an inhibitory G protein (Gi/o) that reduces the neuron's excitability — slowing its firing, dampening the release of pain-signalling chemicals, and producing a general quieting of activity in relevant circuits.

This inhibitory action operates across several brain regions at once. In the spinal cord and brainstem it blocks pain signals before they reach conscious awareness. In the limbic system it suppresses the emotional distress that normally accompanies pain. In the brainstem's respiratory control centres it slows the automatic drive to breathe — the mechanism behind overdose.

Relevance to substances & effects

Full agonists at the μ receptor — morphine, heroin (which converts to morphine in the body), oxycodone, hydromorphone, and fentanyl — bind and activate it maximally, producing strong analgesia, sedation, warmth, and, at sufficient doses, intense euphoria.

Partial agonists such as buprenorphine also bind the μ receptor but activate it only partially, producing a ceiling on both therapeutic and adverse effects. This property is why buprenorphine is used in opioid use disorder treatment: it occupies the receptor and reduces cravings without producing the same depth of respiratory depression a full agonist does.

Antagonists — naloxone and naltrexone — bind the receptor without activating it, blocking opioids from taking effect. Naloxone rapidly displaces other opioids from the receptor and is the primary pharmacological treatment for opioid overdose.

Tolerance & dependence

Repeated activation of the μ receptor drives tolerance through a process called receptor desensitisation and downregulation: the cell reduces the number of available receptors and blunts their response, requiring higher doses to achieve the same effect.

Physical dependence follows because the body adapts to sustained receptor suppression. When opioids are removed or blocked, the suddenly uninhibited circuits produce withdrawal: restlessness, muscle aches, nausea, sweating, and anxiety. The severity and time course depend on which opioid was used and for how long.

Psychological craving is thought to involve long-term changes in dopamine and reward circuitry that μ receptor activation sets in motion, and these changes can persist well after physical withdrawal resolves.

Clinical · risk note

The most acute risk associated with μ receptor agonism is respiratory depression. Because the receptor is expressed in brainstem nuclei that set the rhythm of breathing, high-dose or rapid opioid exposure can suppress breathing to the point of hypoxia and death.

The risk is sharply increased when opioids are combined with other central nervous system depressants — benzodiazepines, alcohol, and certain anaesthetics — because each suppresses respiration through separate mechanisms that compound one another. Tolerance to euphoria and sedation develops faster than tolerance to respiratory depression, meaning a person with high opioid tolerance is not proportionally protected against overdose.